Pierre Geborek

affiliated with the university
More filtering options
  1. 1984
  2. Acute alveolitis and sulphasalazine in rheumatoid arthritis

    Pierre Geborek, M Monti, F Sandblad & Frank Wollheim, 1984, In : Clinical and Experimental Rheumatology. 2, 3, p. 279-280

    Research output: Contribution to journalArticle

  3. 1987
  4. 1988
  5. Measurement of oxygen and carbon dioxide partial pressures in synovial fluid after tonometry

    Pierre Geborek, B Lindoff & Sven Valind, 1988, In : Clinical Physiology. 8, 4, p. 427-432

    Research output: Contribution to journalArticle

  6. Mononuclear cells recovered from inflammatory synovial membrane using fine-needle biopsy

    Pierre Geborek, Magnhild Sandberg Wollheim & Frank Wollheim, 1988, In : Rheumatology International. 8, 3, p. 101-105

    Research output: Contribution to journalArticle

  7. 1989
  8. 1990
  9. IgM-ANCA in a patient with systemic vasculitis without pulmonary involvement

    L Nässberger & Pierre Geborek, 1990, In : Clinical Nephrology. 34, 6, p. 280-280

    Research output: Contribution to journalArticle

  10. MR imaging of the knee in acute rheumatoid arthritis: synovial uptake of gadolinium-DOTA

    Ann G Björkengren, Pierre Geborek, Urban Rydholm, Stig Holtås & Holger Petterson, 1990, In : American Journal of Roentgenology: diagnostic imaging and related sciences . 155, 2, p. 329-332

    Research output: Contribution to journalArticle

  11. 1991
  12. 1992
  13. 1993
  14. 1994
  15. Prevention of joint destruction in antigen-induced arthritis

    Frank Wollheim, Hans Telhag, Anders Henricsson & Pierre Geborek, 1994, In : Clinical Immunology and Immunopathology. 70, 1, p. 19-21

    Research output: Contribution to journalArticle

  16. 1995
  17. Hip involvement in early rheumatoid arthritis

    Kerstin Eberhardt, Eva Fex, Kjell Johnsson & Pierre Geborek, 1995, In : Annals of the Rheumatic Diseases. 54, 1, p. 45-48

    Research output: Contribution to journalArticle

  18. 1997
  19. 2000
  20. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis

    Pierre Geborek & Tore Saxne, 2000, In : Rheumatology. 39, 10, p. 1159-1161

    Research output: Contribution to journalArticle

  21. 2001
  22. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)

    Agneta Scheja, Anita Åkesson, Pierre Geborek, Marie Wildt, Claes B Wollheim, Frank Wollheim & Ulrich M Vischer, 2001, In : Arthritis Research & Therapy. 3, 3, p. 178-182

    Research output: Contribution to journalArticle

  23. 2002
  24. 2003
  25. 2004
  26. 2005
  27. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

    J Askling, CM Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundstrom, L Bertilsson, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, L Klareskog & N Feltelius, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1414-1420

    Research output: Contribution to journalArticle

  28. No increase of severe infections in RA patients treated with TNF-blockers

    L T H Jacobsson, C Turesson, Anders Gülfe, M C Kapetanovic, Ingemar Petersson, Tore Saxne & Pierre Geborek, 2005, In : Annals of the Rheumatic Diseases. 64, Suppl. 3, p. 461-462

    Research output: Contribution to journalPublished meeting abstract

  29. Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

    Pierre Geborek, E Nitelius, S Noltorp, H Petri, L Jacobsson, L Larsson, Tore Saxne & I Leden, 2005, In : Annals of the Rheumatic Diseases. 64, 12, p. 1805-1807

    Research output: Contribution to journalLetter

  30. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

    N Feltelius, CM Fored, P Blomqvist, L Bertilsson, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 2, p. 246-252

    Research output: Contribution to journalArticle

  31. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, L Coster, Pierre Geborek, Lennart Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne, V Romanus, L Klareskog & N Feltelius, 2005, In : Arthritis and Rheumatism. 52, 7, p. 1986-1992

    Research output: Contribution to journalArticle

  32. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

    J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelus, L Coster, Pierre Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, Tore Saxne & L Klareskog, 2005, In : Annals of the Rheumatic Diseases. 64, 10, p. 1421-1426

    Research output: Contribution to journalArticle

  33. 2006
  34. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C. Kapetanovic & Tore Saxne, 2006, In : Arthritis and Rheumatism. 54, 12, p. 3782-3789

    Research output: Contribution to journalArticle

  35. Predictors of infusion reactions during infliximab treatment in patients with arthritis.

    Meliha C Kapetanovic, Lotta Larsson, Lennart Truedsson, Gunnar Sturfelt, Tore Saxne & Pierre Geborek, 2006, In : Arthritis Research and Therapy. 8, p. 1-7 R131.

    Research output: Contribution to journalArticle

  36. Swedish registers to examine drug safety and clinical issues in RA

    J Askling, CM Fored, Pierre Geborek, LTH Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad & L Klareskog, 2006, In : Annals of the Rheumatic Diseases. 65, 6, p. 707-712

    Research output: Contribution to journalReview article

  37. 2007
  38. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic & Tore Saxne, 2007, In : Ugeskrift for Laeger. 169, 5, p. 420-423

    Research output: Contribution to journalArticle

  39. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

    Johan Askling, C. Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Nils Feltelius, Lars Coster, Pierre Geborek, Lennart Jacobsson, Staffan Lindblad, Jorgen Lysholm, Solbritt Rantapaa-Dahlqvist, Tore Saxne, Ronald F. van Vollenhoven & Lars Klareskog, 2007, In : Annals of the Rheumatic Diseases. 66, 10, p. 1339-1344

    Research output: Contribution to journalArticle

Previous 1 2 3 Next